Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
HQ
Founded
2014
Point72 Asset Management is a global hedge fund that invests in multiple asset classes and strategies worldwide. The firm focuses on delivering risk-adjusted returns and adheres to the highest ethical standards while fostering industry talent. Point72 typically participates in various investment stages, including pre-seed, seed, Series B, Series C, and Series E rounds.
Notable portfolio companies include Arch Oncology, Atomic Industries, Biotheryx, Delfi Diagnostics, Korro Bio, LÜK Network, and Vestwell. The firm is led by key decision-makers who emphasize innovation and entrepreneurial thinking. Point72 offers unique value-add services by empowering its team to build expertise and challenge consensus, ensuring that great ideas are nurtured and brought to life across the firm.
1
As of August 24, 2024
Also Known As
Point72, L.P.
Operating Status
Active
Point72 Asset Management Address
Warsaw,
Masovian Voivodeship
Poland
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts